Similar to other solid tumors, programmed cell death protein 1 (PD-1) inhibitors nivolumab and pembrolizumab have been approved for patients with recurrent/metastatic head and neck squamous cell carcinomas including OSCC. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.